HepaLife Announces Scientific Presentation of PBS-1 Cell Line at International Influenza Meeting
HepaLife Completes Private Placement for $2.5 Million
HepaLife Expands Management Team on Heels of Favorable Outcomes of First-of-Its-Kind Bioartificial Liver Device
HepaLife Achieves Major Milestone in Development of Artificial Liver Device
HepaLife's Cells for Artificial Liver Device Significantly Outperform Most-Widely Used Human Liver Cell Line
HepaLife's Patented ''PBS-1'' Cells for Avian Flu Vaccines Outperform Current Cell System by 500%
HepaLife Announces Appointment of Senior Medical Device and Healthcare Executive to the Board of Directors
Positive Research Findings Accelerate HepaLife's Development of Artificial Liver Device
Internationally Renowned Expert in Artificial Liver Device Development Joins HepaLife
